

# Blue Cross and Blue Shield of Minnesota and Blue Plus Commercial Prior Authorization/Admission Notification Requirements

#### Overview

Prior Authorization is required for various services, procedures, prescription drugs, and medical devices. This document contains the full list of services, procedures, prescription drugs, and medical devices that require prior authorization/notification for Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) commercial products.

The prior authorization process determines whether services are medically necessary and appropriate based on clinical coverage criteria and is not a reflection of a member's benefits or eligibility. Benefits and eligibility must be verified each time a member seeks services. All applicable terms and conditions of the member's plan including exclusions, deductibles, copayments, and coinsurance provisions continue to apply with an approved prior authorization/notification.

A notification is a process whereby the provider or subscriber informs Blue Cross of a planned, unplanned or emergency service. All inpatient admissions require notification. Upon receipt of an admission notification, when prior authorization is required, the admission will be reviewed for medical necessity and appropriateness. As needed throughout an inpatient stay, we will review clinical records to determine medical necessity and appropriateness and to help the member when discharged.

## **Submitting Prior Authorizations/Notifications**

Providers may submit prior authorization and notification requests on <u>Availity.com</u>. If unable to submit request using Availity, provider may submit request to Blue Cross Utilization Management Department using the appropriate form: <u>Pre-Authorization/Pre-Certification/Notification Forms</u>

When submitting a prior authorization or notification request, please ensure the following are available:

- The patient name (as it appears on the member's identification card)
- The patient subscriber ID, including alpha prefix, and group number
- The patient date of birth
- Name of ordering/admitting physician and NPI number
- Name of servicing/rendering physician and NPI number
- Diagnosis/CPT/HCPCS codes pertinent to the requested service and narrative description of service requested
- Clinical documentation to support the service request based on the relevant Medical Policy's documentation requirements
- Requestor's contact name, phone and fax number and location

To assure timely processing, please submit your request on <a href="Availity.com">Availity.com</a>.

Access the Blue Cross and Blue Shield of Minnesota Medical and Behavioral Health Policies on our website. Change Healthcare's InterQual® criteria are available upon request.



A copy of any policy or other clinical criteria used to make a medical necessity determination may be requested by calling Provider Services at 1-800-262-0820 or (651) 662-5200.

The below list includes the standard prior authorization (PA)/notification requirements for Commercial products based on today's date. Upcoming changes to PA requirements can be found in the monthly Provider Bulletins published online at <a href="bluecrossmn.com/providers/forms-and-publications">bluecrossmn.com/providers/forms-and-publications</a> or by using the Authorizations tool in the Availity® provider portal. Additional PA requirements may also apply based on the member's group benefits.

The HCPCS/CPT/NUBC codes listed are included for informational purposes only and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

| Blue Cross and Blue Shield of Minnesota and Blue Plus Commercial Notifications |  |  |
|--|--|--|
| Notification Only:   | <ul> <li>Acute Medical and Acute Behavioral Health Inpatient Admissions         <ul> <li>Admission notification is required for all admissions</li> <li>Continued stay notification is required if applicable, when the member is still in after the initially allowed days</li> <li>Discharge details must be provided for every admission</li> </ul> </li> <li>Outpatient Dialysis Services         <ul> <li>Notification is required for all outpatient dialysis services</li> <li>Upon initiation of outpatient dialysis, please complete Medicare CMS 2728 form and submit your request on Availity.com or fax to 651-662-2810. The CMS 2728 form must be used for both Medicare and non-Medicare subscribers.</li> <li>If the subscriber is Medicare eligible, please complete entire form.</li> <li>If the subscriber is not Medicare eligible, please complete only sections A-C.</li> </ul> </li> </ul> |  |



# Blue Cross and Blue Shield of Minnesota and Blue Plus **Commercial Prior Authorization Requirements**

| Medical Policy<br>Number or Criteria | Service Category  | CPT/HCPCS/Revenue Codes  |  |
|--------------------------------------|---|--|--|
| Radiology, Genetic                   | Radiology, Genetic Testing  |  |  |
| VI-16                                | Genetic Testing for Hereditary Breast and/or Ovarian Cancer   | 0102U, 0103U, 81162, 81163, 81164, 81165, 81166, 81167, 81212, 81215, 81216, 81217, 81432, 81433 |  |
| Behavioral Health                    |   |  |  |
| X-43                                 | Autism Spectrum Disorders: Assessment and Early Intensive Behavioral Intervention (EIBI) – greater than 9 hours/week (MN and participating border county providers) | H0032, H2014, H2017, H2019, 0362T, 0373T, 97151, 97152, 97153, 97154, 97155, 97156, 97157, 97158 |  |
| InterQual                            | Eating Disorder Residential Services (MN providers)   | No specific coding   |  |
| InterQual                            | Mental Health Residential Admissions (MN providers)   | No specific coding   |  |
| InterQual                            | Partial Hospitalization (MN and participating border county providers)  | H0035<br>Revenue Codes: 0912, 0913   |  |
| X-45                                 | Psychological & Neuropsychological Testing  | 96116, 96121, 96130, 96131, 96132, 96133, 96136, 96137, 96138, 96139, 96146                      |  |
| InterQual                            | Substance Use Disorder Residential Admissions (MN providers)  | No specific coding   |  |

<sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.



| Blue Drose <sup>a</sup> and Stue Shield <sup>a</sup> of Minnesote and Stue Pi<br>Independent Isonaecs of the Stue Cross and Blue Shie  | Commercial Prior Authorization/No   | vtification List           |
|--|---|----------------------------|
| Cosmetic Services  The list below is considered examples of cosmetic services and will not be covered unless BCBSMN considers the request eligible as reconstructive surgery under the terms of a member's contract. This list is not all inclusive.   |   |                            |
| IV-82  | Liposuction   | 15876, 15877, 15878, 15879 |
| Drugs & Injectables under the Medical Benefit  Electronic medical drug prior authorization requests can be submitted electronically to Blue Cross thru <u>Availity.com</u> or transmitted <u>electronically</u> through an integrated electronic medical record (EMR) system. See the <u>Medical Drug Exclusion List</u> for drug guidelines that apply. |   |                            |
| II-161   | Abatacept (Orencia®)  | J0129                      |
| II-107   | <ul> <li>Advanced Pharmacologic Therapies for Pulmonary Arterial Hypertension:</li> <li>Epoprestenol (Flolan® or Veletri®)</li> <li>Sildenafil (Revatio®)</li> <li>Treprostinil (Remodulin®)</li> </ul> | J1325, J3285               |
| II-238   | Afamelanotide (Scenesse®)   | J7352                      |
| II-26  | Agalsidase beta (Fabrazyme®)  | J0180                      |
| II-184   | Alemtuzumab (Lemtrada®)   | J0202                      |
| II-186   | Alglucosidase alfa (Lumizyme®)  | J0221                      |
| II-206   | Alpha-1 Proteinase Inhibitors (Aralast NP™, Glassia®, Prolastin-C®, Zemaira®)   | J0256, J0257               |
| II-187   | Axicabtagene Ciloleucel (Yescarta™)   | C9399, J3490, J3590, Q2041 |
| II-152   | Belimumab (Benlysta®)   | J0490                      |
| II-203   | Benralizumab (Fasenra®)   | J0517                      |
| II-199   | Bezlotoxumab (Zinplava®)  | J0565                      |
| II-16  | Botulinum Toxin (Botox®, Dysport®, Myobloc®, Xeomin®)   | J0585, J0586, J0587, J0588 |
| II-231   | Brexanolone (Zulresso™)   | J1632                      |

<sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **4** Updated: 5/31/2021



| II-245 | Brexucabtagene autoleucel (Tecartus®)  | J3490, J3590, J9999, Q2053 |
|--------|--|----------------------------|
| II-212 | Burosumab (Crysvita®)  | J0584                      |
| II-228 | Caplacizumab (Cablivi™)  | C9047, J3490               |
| II-176 | Cerliponase alfa (Brineura™)   | J0567                      |
| II-179 | Certolizumab Pegol (Cimzia®)   | J0717                      |
| II-235 | Crizanlizumab (Adakveo®)   | J0791                      |
| II-196 | Eculizumab (Soliris®)  | J1300                      |
| II-178 | Edaravone (Radicava™)  | J1301                      |
| II-218 | Elosulfase alfa (Vimizim®)   | J1322                      |
| II-204 | Emapalumab-Izsg (Gamifant®)  | J9210                      |
| II-227 | Enzyme Replacement Therapy for the Treatment of Adenosine Deaminase  Severe Combined Immune Deficiency:  • Elapegademase (Revcovi™)  • Pegademase bovine (Adagen®) | C9399, J2504, J3590        |
| II-240 | Eptinezumab (Vyepti™)  | J3032                      |
| II-226 | Esketamine Nasal Spray (Spravato™)   | C9399, J3490, S0013        |
| II-173 | Fosdenopterin (Nulibry™)   | C9399, J3490, J3590        |
| II-217 | Galsulfase (Naglazyme®)  | J1458                      |

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **5** Updated: 5/31/2021



|        | Commercial nor Admonization  | Tourisdan Liet  |
|--------|--|---|
| II-234 | Givosiran (Givlaari™)  | J0223   |
| II-180 | Golimumab (Simponi Aria®)  | J1602   |
| II-215 | Idursulfase (Elaprase®)  | J1743   |
| II-51  | Immunoglobulin (IV or Sub Q IgG) Replacement Therapy   | J1459, J1554, J1555, J1556, J1557, J1559, J1561, J1562, J1566, J1568, J1569, J1572, J1575, J1558, J1599, 90283, 90284   |
| 11-244 | Inebilizumab (Uplizna™)  | J1823   |
| II-97  | Infliximab® (Remicade®)  Note: Infliximab biosimilars [e.g., Inflectra™ (Q5103), Renflexis™ (Q5104), Ixifi™ (Q5109), Avsola™ (Q5121) are excluded from coverage under the medical benefit. See the Medical Drug Exclusion List for guidelines.   | J1745   |
| II-29  | Intra-Articular Hyaluronan Injections for Osteoarthritis  No PA required for preferred drugs, Synvisc and Synvisc-One (J7325)  PA required for non-preferred drugs ( <i>medical</i> exception requests only): Durolane, Euflexxa, Gel-One, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, MonoVisc, OrthoVisc, Supartz, Supartz FX, Synojoynt, Triluron, TriVisc, Visco-3  See the Medical Drug Exclusion List for guidelines. | PA required for non-preferred drugs ( <i>medical</i> exception requests only): J7318, J7320, J7321, J7322, J7323, J7324, J7326, J7327, J7328, J7329, J7331, J7332 |
| II-214 | Intravenous Enzyme Replacement Therapy for Gaucher Disease (Cerezyme®, Elelyso®, Vpriv®)   | J1786, J3060, J3385   |

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **6** Updated: 5/31/2021



| II-243<br>II-71<br>II-216 | Intravenous Iron Replacement Therapy  • Ferumoxytol (Feraheme®)  • Ferric Carboxymaltose (Injectafer®)  • Ferric Derisomaltose (Monoferric®)  Intravitreal Angiogenesis Inhibitors for Treatment of Retinal and Choroidal Vascular Conditions (Beovu™, Eylea®, Lucentis®, Macugen®)  Laronidase (Aldurazyme®)  Lisocabtagene Maraleucel (Breyanzi®) | J1437, J1439, Q0138  J0178, J0179, J2503, J2778  J1931 |
|---------------------------|---|--|
|                           | Choroidal Vascular Conditions (Beovu™, Eylea®, Lucentis®, Macugen®)  Laronidase (Aldurazyme®)   | J1931  |
| II-216                    |   |  |
|                           | Lisocabtagene Maraleucel (Breyanzi®)  |  |
| II-173                    |   | C9399, J3490, J3590, J9999                             |
| II-248                    | Lumasiran (Oxlumo™)   | C9074, J3490, J3590                                    |
| II-237                    | Luspatercept (Reblozyl®)  | J0896  |
| II-201                    | Mepolizumab (Nucala®)   | J2182  |
| II-49                     | Natalizumab (Tysabri®)  | J2323  |
| II-171                    | Nusinersen (Spinraza™) – a medical drug PA will be required every 6 months  | J2326  |
| II-185                    | Ocrelizumab (Ocrevus®)  | J2350  |
| II-34                     | Omalizumab (Xolair®)  | J2357  |
| II-230                    | Onasemnogene abeparvovec (Zolgensma®)   | J3399  |
| II-62                     | Palivizumab (Synagis®) – Respiratory Syncytial Virus (RSV) Prophylaxis  | 90378  |
| II-220                    | Patisiran (Onpattro ™)  | J0222  |
| II-241                    | Peanut allergen powder (Palforzia®) & Peanut allergy patch (*Viaskin® Peanut - PA required upon FDA Approval)   | J3490  |

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **7** Updated: 5/31/2021



| before data for the manus of the David Command Base Divid Association Command |   |                            |  |
|---|---|----------------------------|--|
| II-147  | Pegloticase (Krystexxa®)  | J2507                      |  |
| II-102  | Pharmacologic Therapies for Hereditary Angioedema [Berinert®, Cinryze®, ecallantide (Kalbitor®), Ruconest®] | J0596, J0597, J0598, J1290 |  |
| II-229  | Ravulizumab (Ultomiris™)  | J1303                      |  |
| II-202  | Reslizumab (Cinqair®)   | J2786                      |  |
| II-47   | Rituximab (Rituxan®), non-oncologic indications only  | J9312                      |  |
| II-211  | Romiplostim (Nplate®), non-oncologic indications only   | J2796                      |  |
| II-236  | Romosozumab (Evenity®)  | J3111                      |  |
| II-200  | Sebelipase alfa (Kanuma®)   | J2840                      |  |
| II-239  | Teprotumumab (Tepezza™)   | J3241                      |  |
| II-222  | Tildrakizumab (Ilumya ™)  | J3245                      |  |
| II-183  | Tisagenlecleucel (Kymriah™)   | C9399, J3490, J3590, Q2042 |  |
| II-181  | Tocilizumab (Actemra®), non-oncologic indications only  | J3262                      |  |
| II-168  | Ustekinumab (Stelara®)  | J3357, J3358               |  |
| II-182  | Vedolizumab (Entyvio®)  | J3380                      |  |
| II-219  | Vestronidase alfa (Mepsevii™)   | J3397                      |  |
| II-188  | Voretigene Neparvovec (Luxturna™)   | J3398                      |  |
| Equipment/Produc  | Equipment/Products/Prosthetic/Supplies  |                            |  |
| VII-11  | Functional Neuromuscular Electrical Stimulation (UpperExtremity)  | E0764, E0770               |  |
|   |   |                            |  |

<sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **8** Updated: 5/31/2021



Blue Drose" and Stue Shield" of Minnesots and Stue Plus" are nongraindependent licensess of the Stue Cross and Blue Shield Association. Commercial Prior Authorization/Notification List

| VII-16            | Microprocessor Controlled Prostheses for the Lower Limb   | K1014, L2006, L5856, L5857, L5858, L5859, L5973   |
|-------------------|---|---|
| VII-60            | Myoelectric Prosthesis for the Upper Limb   | L6026, L6715, L6880, L6925, L6935, L6945, L6955, L6965, L6975, L7007, L7008, L7009, L7045, L7190, L7191, L8701, L8702 |
| VII-35            | Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders in the Home (Vest Percussor) | E0481, E0483  |
| VII-52            | Speech Generating Devices (SGD)   | E1902, E2351, E2500, E2502, E2504, E2506, E2508, E2510, E2511, E2512, E2599   |
| Contract Benefits | Unlisted DME over \$500   | No specific coding  |
| II-91             | Wearable Cardioverter-Defibrillators  | K0606, K0607, K0608, K0609  |

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.



|                  |   | Manual (Non-Motorized) Wheelchair: E1050, E1060, E1070, E1083, E1084, E1085, E1086, E1087, E1088, E1089, E1090, E1092, E1093, E1100, E1110, E1130, E1140, E1150, E1160, E1170, E1171, E1172, E1180, E1190, E1195, E1161, E1200, E1220, E1221, E1222, E1223, E1224, E1229, E1231, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E1240, E1250, E1260, E1270, E1280, E1285, E1290, E1295, K0001, K0002, K0003, K0004, K0005, K0006, K0007, K0008, K0009  |
|------------------|---|--|
|                  | Wheelchairs – Mobility Assistive Equipment  | Power Operated Vehicles (POV): E1230, K0800, K0801, K0802, K0806, K0807, K0808, K0812  |
| VII-04           | (Manual & Power) & Scooters— Wheelchair Purchase only erly Home Health Care/Outpatient Therapies/Acupuncture)   | Motorized/Power Wheelchair (PWC): E1239, K0010, K0011, K0012, K0013, K0014, K0813, K0814, K0815, K0816, K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829, K0835, K0836, K0837, K0838, K0839, K0840, K0841, K0842, K0843, K0848, K0849, K0850, K0851, K0852, K0853, K0854, K0855, K0856, K0857, K0858, K0859, K0860, K0861, K0862, K0863, K0864, K0868, K0869, K0870, K0871, K0877, K0878, K0879, K0880, K0884, K0885, K0886, K0890, K0891, K0898, K0899  Specialized Seating/Options/Accessories: E1002, E1003, E1004, E1005, E1006, E1007, E1008, E1009, E1010, E1037, E1038, E1039, E1225, E1226, E2230, E2300, E2301, K0669, K0830, K0831 |
| III 04           | Acupuncture:     Fully-Insured and Self-Insured – Prior authorizations will be required   |  |
| III-01           | after 20 visits. This applies to member contracts with benefit maximums beyond 20 visits. Contracts with a benefit maximum of 20 visits per calendar year – no PA required. | 97810, 97811, 97813, 97814   |
| III-01<br>II-160 | beyond 20 visits. Contracts with a benefit maximum of 20 visits per   | 97810, 97811, 97813, 97814<br>A0430, A0431, A0435, A0436, S9960, S9961   |
|                  | beyond 20 visits. Contracts with a benefit maximum of 20 visits per calendar year – no PA required.   |  |

Page | **10** Updated: 5/31/2021

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.



| InterQual  | <ul> <li>Home Health Skilled Nursing Visits</li> <li>Fully Insured – After 20 visits per calendar year</li> <li>Self-Insured – After 20 visits per calendar year or per Contract<br/>Requirement</li> </ul> | G0162, G0299, G0300, G0493, G0494, G0495, G0496, S9097, S9098, S9123, S9124, T1001, T1022, T1030, T1031, 99500, 99505, 99506, 99507, 99509, 99511, 99600  Revenue codes: 0550, 0551, 0552, 0559 |  |
|--|---|---|--|
| InterQual  | Home Health Aide  | G0156, S9122, T1004, T1021  Revenue Codes: 0570, 0571, 0572, 0579   |  |
| No authori   | No authorization needed for the following Home Care Services ONLY: Occupational Therapy, Physical Therapy, Respiratory Therapy, Speech, Language Therapy, Social Worker or Dietitian.                       |   |  |
| Benefit Contract /<br>InterQual  | Inpatient Hospice/Palliative Care   | No specific coding  |  |
| Inpatient Facility - The following require Prior Authorization as soon as the admission is ordered/scheduled, but no later than two working days after the admission occurs. |   |   |  |
| InterQual  | Inpatient Rehabilitation Admissions   | No specific coding  |  |
| InterQual  | Long Term Acute Care (LTAC)   | No specific coding  |  |
| InterQual  | Skilled Nursing Facility (SNF)  | No specific coding  |  |
| InterQual  | Out of Country: All inpatient admissions  | No specific coding  |  |

| Medical Policy Number or<br>Criteria | Service Category         | CPT/HCPCS/Revenue Codes   |
|--------------------------------------|--------------------------|---|
| Medical/Procedures/Surgical (        | Inpatient or Outpatient) |   |
| IV-01                                | Balloon Ostial Dilation  | 31295, 31296, 31297, 31298, 31299   |
| IV-19                                | Bariatric Surgery        | 43644, 43645, 43770, 43771, 43772, 43773, 43774, 43775, 43842, 43843, 43845, 43846, 43847, 43848, 43850, 43855, 43860, 43865, 43886, 43887, 43888 |

<sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.



Blue Crose\* and Blue Shield\* of Minnesots and Blue Plus\* are nongraindependent licenses of the Blue Cross and Blue Shield Association Commercial Prior Authorization/Notification List

| IV-17  | Blepharoplasty and Brow Ptosis Repair  | 15820, 15821, 15822, 15823, 67900, 67901, 67902, 67903, 67904, 67906, 67908  |
|--------|--|--|
| IV-14  | Breast Implant, Removal or Replacement (No PA required for breast reconstruction due to breast cancer or high risk of breast cancer due to known genetic mutation) | C1789, L8600, 11970, 19325, 19328, 19330, 19340, 19342, 19396  |
| IV-143 | Closure Devices for Patent Foramen Ovale and Atrial Septal   | 93580  |
| II-207 | Corneal Collagen Cross-Linking   | 0402T, J2787   |
| IV-123 | Gender Affirming Procedures for Gender Dysphoria   | 55970, 55980, 56805, 57291, 57292, 57335   |
| IV-71  | Gynecomastia Surgery   | 19300  |
| IV-80  | Implanted Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea   | 0466T, 0467T   |
| IV-169 | Percutaneous Left Atrial Appendage Occluder Devices  | 33340  |
| IV-16  | Orthognathic Surgery   | D7941, D7943, D7944, D7945, D7946, D7947, D7948, D7949, 21120, 21121, 21122, 21123, 21125, 21127, 21141, 21142, 21143, 21145, 21146, 21147, 21150, 21151, 21154, 21155, 21159, 21160, 21188, 21193, 21194, 21195, 21196, 21198, 21199, 21206, 21208, 21209 |
| IV-24  | Panniculectomy / Excision of Redundant Skin or Tissue  | 15819, 15825, 15828, 15829, 15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15847, 56620, 56625   |
| IV-95  | Percutaneous Facet Joint Denervation   | 64633, 64634, 64635, 64636   |
| IV-32  | Reduction Mammoplasty  | 19318  |
| IV-126 | Sacroiliac Joint Fusion  | 27279, 27280   |
| IV-87  | Spinal Fusion (Lumbar)   | 22533, 22558, 22612, 22630, 22633, 22634, 22800, 22802, 22804, 22808, 22810, 22812   |
| IV-149 | Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) for Aortic Stenosis  | 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368,33369   |
| IV-152 | Transcatheter Mitral Valve Repair (TMVR)   | 0345T, 33418, 33419  |
|        |  |  |

<sup>&</sup>lt;sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **12** Updated: 5/31/2021



| Blue Cross* at | nd Slow Shiel | of at Mi     | nnesota and       | f Short Phot   | are nongraf       |
|----------------|---------------|--------------|-------------------|--|-------------------|
| Inchesendant I | frances and a | the Miles of | Second area of E. | Security States and Assessment States and As | Secured asiles at |

|   | Commercial i noi / tationzation/140t  |   |
|---|---|---|
| II-164  | Tumor Treating Fields Therapy   | A4555, E0766  |
| IV-07   | Uvulopalatopharyngoplasty (UPPP – Surgical Treatment of Obstructive Sleep Apnea)  | 42145   |
| IV-144  | Viscocanalostomy and Canaloplasty for the Treatment of Glaucoma   | 66174, 66175  |
| <b>Transplants</b><br>Consult, Evaluation, Workup & Hun | nan Leukocyte Antigen (HLA) typing and testing also called Tissue   | Typing, do not require prior authorization/notification.  |
| IV-09   | Islet Transplantation   | 0584T, 0585T, 0586T, 48160, G0341, G0342, G0343, S2102  |
| IV-128  | Organ Transplantation (No PA required for Kidney and Cornea)  | \$2053, \$2054,\$2055, \$2060,\$2061,\$2065,\$2152,\$0494T,\$0495T,\$0496T,\$2850,\$2851,\$2852,\$2853,\$2854,\$2855,\$2856,\$33930,\$33933,\$33935,\$33940,\$33944,\$33945,\$44132,\$44133,\$44135,\$44136,\$44137,\$44715,\$44720,\$44721,\$47133,\$47135,\$47140,\$47141,\$47142,\$47143,\$47144,\$47145,\$47146,\$47147,\$48550,\$48551,\$48552,\$48554,\$48556 |
|   |   | S2140, S2142, S2150, 38204, 38205, 38208, 38209, 38210, 38211,38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243  |
| Specialty Utilization Managem                           |   |   |
| eviCore (Cardiology)                                    | Cardiac Advanced Imaging (including Echo Stress Testing, Nuclear Stress Tests / MPI, Cardiac MRI, Cardiac PET, and CCTAs) | (FULLY INSURED MEMBERS ONLY)  For a current list of code(s) please visit:   |
| eviCore (Cardiology)                                    | Cardiac Catheterization, Cardiac Resynchronization Implantable Devices  | eviCore Healthcare Specialty Utilization Management Clinical Guidelines   |
| eviCore (Musculoskeletal)                               | Interventional Pain Management (Spine/Joint Injections, Stimulators, Blocks, RF Ablation, etc.)                           |   |
| eviCore (Musculoskeletal)                               | Knee/Hip/Shoulder Surgery   |   |

<sup>1</sup> Services, procedures, prescription drugs and medical devices may be referred to as simply 'service(s)' in the remainder of this document.

Page | **13** Updated: 5/31/2021



Blue Cross\* and Slux Shield\* of Minnesots and Slux Plus\* are nongrindependent, leanuses of the Slux Cross and Blue Shield Association

# Commercial Prior Authorization/Notification List

| eviCore (Medical Oncology)  | Medical Oncology (Primary and Supportive Cancer Treatment Drugs)   |
|-----------------------------|--|
| eviCore (Lab Management)    | Molecular and Genomic Testing                                      |
| eviCore (Radiology)         | Radiology Advance Imaging (MRI, MRA, PET, CT, and Nuclear Studies) |
| eviCore (Radiation Therapy) | Radiation Therapy  |
| eviCore (Sleep Management)  | Sleep Management   |
| eviCore (Musculoskeletal)   | Spine Surgery  |

If a question arises regarding a specific service or to verify if prior authorization or notification is required or questions pertaining to member benefits, please use Availity® provider portal or contact Provider Services at 1-800-262-0820 or (651) 662-5200.